New biologics and long-acting agents (WAYPOINT & ANCHOR) reshape CRSwNP landscape
Key Questions
What are tezepelumab and depemokimab, and how do they benefit CRSwNP patients?
Tezepelumab is an anti-TSLP biologic, and depemokimab is an anti-IL-5 agent. Both show improvements in SNOT-22 scores and reduce the need for surgery and steroids in chronic rhinosinusitis with nasal polyps (CRSwNP). They complement dupilumab, particularly with 48% asthma comorbidity overlap noted in product information.
What limitations exist in the data for these new biologics in CRSwNP?
No data is available yet on aspirin-exacerbated respiratory disease (AERD). Monitoring through biomarkers, registries, FeNO, and eosinophils is recommended for better personalization.
How does GINA 2025 relate to these biologics for CRSwNP and asthma?
GINA 2025/2026 updates reinforce Type 2 biologics for personalized asthma care. This supports their use in CRSwNP due to high asthma comorbidity, with FeNO testing helping assess airway inflammation in related symptoms like coughing and wheezing.
Tezepelumab (anti-TSLP) and depemokimab (anti-IL-5) show SNOT-22 gains, less surgery/steroids in CRSwNP. No AERD data yet; complements dupilumab (PI notes 48% asthma comorbidity overlap)—track biomarkers/registries/FeNO/eosinophils; GINA 2025/2026 reinforces Type 2 biologics for personalized care.